SG11201806512VA - Copanlisib biomarkers - Google Patents
Copanlisib biomarkersInfo
- Publication number
- SG11201806512VA SG11201806512VA SG11201806512VA SG11201806512VA SG11201806512VA SG 11201806512V A SG11201806512V A SG 11201806512VA SG 11201806512V A SG11201806512V A SG 11201806512VA SG 11201806512V A SG11201806512V A SG 11201806512VA SG 11201806512V A SG11201806512V A SG 11201806512VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- biomarkers
- pct
- copanlisib
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 10 August 2017 (10.08.2017) WIPO I PCT (10) International Publication Number WO 2017/134030 Al 111111111111110111011111111111010111110 011101111110111110111110111111111110111111 (51) International Patent Classification: C12Q 1/68 (2006.01) A61K 31/519 (2006.01) (21) International Application Number: PCT/EP2017/051988 (22) International Filing Date: 31 January 2017 (31.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/289,715 1 February 2016 (01.02.2016) US (71) Applicant: BAYER PHARMA AKTIENGESELL- SCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). (72) Inventors: PENA, Carol; 341 Mount Airy Rd., Basking Ridge, NJ 07920 (US). LIU, Li; 11 Hillside Drive, East Hanover, NJ 07936 (US). CHENG, Jie; 18 Dixon Ln, Belle Mead, NJ 08502 (US). KOCHERT, Karl; Kirschallee 1174, 14469 Potsdam (DE). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) W O 20 17 / 13 4030 Al (54) Title: COPANLISIB BIOMARKERS (57) : This invention provides biomarkers based on the gene expression profiling which can discriminate between patients who response to and/or with longer progression free survival and patients who do not response to and/or with shorter progression free survival from copanlisib treatment in lymphoma including indolent and aggressive NHLs and CLLs. The present invention relates to the use of genes from the BCR, PI3K, NFkB, IL6, inflammation and stromal processes as predictive biomarkers for various human cancers including but not limited to NHLs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662289715P | 2016-02-01 | 2016-02-01 | |
PCT/EP2017/051988 WO2017134030A1 (en) | 2016-02-01 | 2017-01-31 | Copanlisib biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806512VA true SG11201806512VA (en) | 2018-08-30 |
Family
ID=57984907
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806512VA SG11201806512VA (en) | 2016-02-01 | 2017-01-31 | Copanlisib biomarkers |
SG10202007322PA SG10202007322PA (en) | 2016-02-01 | 2017-01-31 | Copanlisib biomarkers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202007322PA SG10202007322PA (en) | 2016-02-01 | 2017-01-31 | Copanlisib biomarkers |
Country Status (16)
Country | Link |
---|---|
US (1) | US20190382839A1 (en) |
EP (1) | EP3411498A1 (en) |
JP (1) | JP2019512003A (en) |
KR (1) | KR20180104129A (en) |
CN (1) | CN109072307A (en) |
AU (1) | AU2017215096A1 (en) |
BR (1) | BR112018015783A2 (en) |
CA (1) | CA3012951A1 (en) |
CL (1) | CL2018002070A1 (en) |
MA (1) | MA43958A (en) |
MX (1) | MX2018009367A (en) |
PH (1) | PH12018501622A1 (en) |
SG (2) | SG11201806512VA (en) |
SV (1) | SV2018005729A (en) |
TN (1) | TN2018000272A1 (en) |
WO (1) | WO2017134030A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
MX2017011635A (en) | 2015-03-09 | 2018-02-09 | Bayer Pharma AG | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations. |
JP6935415B2 (en) | 2016-03-08 | 2021-09-15 | バイエル ファーマ アクチエンゲゼルシャフト | 2-Amino-N- [7-Methoxy-2,3-dihydroimidazole- [1,2-c] quinazoline-5-yl] pyrimidine-5-carboxamides |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
CN109729716B (en) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | PI3K inhibitor combination |
CA3068324A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
EP3498266A1 (en) * | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
MX2020002633A (en) * | 2017-09-08 | 2020-07-13 | Bayer Consumer Care Ag | Formulations of copanlisib. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
CN105316405A (en) * | 2003-07-17 | 2016-02-10 | 环太平洋生物技术有限公司 | Markers for detection of gastric cancer |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
EP2983669B1 (en) * | 2013-04-08 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
RU2666921C2 (en) * | 2013-06-20 | 2018-09-13 | Тайхо Фармасьютикал Ко., Лтд. | METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION |
US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
-
2017
- 2017-01-31 MX MX2018009367A patent/MX2018009367A/en unknown
- 2017-01-31 CA CA3012951A patent/CA3012951A1/en not_active Abandoned
- 2017-01-31 SG SG11201806512VA patent/SG11201806512VA/en unknown
- 2017-01-31 JP JP2018539853A patent/JP2019512003A/en active Pending
- 2017-01-31 BR BR112018015783A patent/BR112018015783A2/en not_active IP Right Cessation
- 2017-01-31 WO PCT/EP2017/051988 patent/WO2017134030A1/en active Application Filing
- 2017-01-31 US US16/074,037 patent/US20190382839A1/en not_active Abandoned
- 2017-01-31 KR KR1020187024848A patent/KR20180104129A/en unknown
- 2017-01-31 EP EP17703689.4A patent/EP3411498A1/en not_active Withdrawn
- 2017-01-31 TN TNP/2018/000272A patent/TN2018000272A1/en unknown
- 2017-01-31 AU AU2017215096A patent/AU2017215096A1/en not_active Abandoned
- 2017-01-31 SG SG10202007322PA patent/SG10202007322PA/en unknown
- 2017-01-31 MA MA043958A patent/MA43958A/en unknown
- 2017-01-31 CN CN201780020052.7A patent/CN109072307A/en active Pending
-
2018
- 2018-07-31 PH PH12018501622A patent/PH12018501622A1/en unknown
- 2018-08-01 CL CL2018002070A patent/CL2018002070A1/en unknown
- 2018-08-07 SV SV2018005729A patent/SV2018005729A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2018002070A1 (en) | 2018-11-16 |
CN109072307A (en) | 2018-12-21 |
US20190382839A1 (en) | 2019-12-19 |
SV2018005729A (en) | 2018-12-05 |
PH12018501622A1 (en) | 2019-06-03 |
EP3411498A1 (en) | 2018-12-12 |
MX2018009367A (en) | 2018-11-09 |
TN2018000272A1 (en) | 2020-01-16 |
BR112018015783A2 (en) | 2018-12-26 |
AU2017215096A1 (en) | 2018-08-09 |
JP2019512003A (en) | 2019-05-09 |
MA43958A (en) | 2018-12-12 |
SG10202007322PA (en) | 2020-09-29 |
WO2017134030A1 (en) | 2017-08-10 |
KR20180104129A (en) | 2018-09-19 |
CA3012951A1 (en) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806512VA (en) | Copanlisib biomarkers | |
SG11201806274SA (en) | Copanlisib biomarkers | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201907857RA (en) | Edible and biodegradable utensils | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201809341PA (en) | Mobile robot | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201805184TA (en) | Combination therapy | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908513RA (en) | Peptides for treatment of diabetes | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |